Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis

Chwalisz K, Kristof Chwalisz, Kristof Chwalisż, Maria Claudia Perez, Perez MC, María Claudia Pérez, Deborah DeManno, DeManno D, Deborah A. DeManno, Craig Winkel, Winkel C, Craig A. Winkel, G. Schubert, Gerd Schubert, Schubert G, Walter Elger, Elger W, W Elger
Endocrine Reviews · 2005 · vol. 26(3) , pp. 423–438 · doi:10.1210/er.2005-0001 · PMID:15857972 · W1986914259
Review OA: closed CC0 ⤵ 105 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Asoprisnil, a selective progesterone receptor modulator, demonstrated effectiveness in reducing uterine bleeding and fibroid volume in uterine fibroid patients and alleviating pain in endometriosis patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands. SPRMs exert clinically relevant tissue-selective progesterone agonist, antagonist, or mixed agonist/antagonist effects on various progesterone target tissues in vivo. Asoprisnil (J867) is the first SPRM to reach an advanced stage of clinical development for the treatment of symptomatic uterine fibroids and endometriosis. Asoprisnil belongs to the class of 11beta-benzaldoxime-substituted estratrienes that exhibit partial progesterone agonist/antagonist effects with high progesterone receptor specificity in animals and humans. Asoprisnil has no antiglucocorticoid activity in humans at therapeutic doses. It exhibits endometrial antiproliferative effects on the endometrium and breast in primates. Unlike progesterone antagonists, asoprisnil does not induce labor in relevant models of pregnancy and parturition. It induces amenorrhea primarily by targeting the endometrium. In human subjects with uterine fibroids, asoprisnil suppressed both the duration and intensity of uterine bleeding in a dose-dependent manner and reduced tumor volume in the absence of estrogen deprivation. In subjects with endometriosis, asoprisnil was effective in reducing nonmenstrual pain and dysmenorrhea. Asoprisnil may, therefore, provide a novel, tissue-selective approach to control endometriosis-related pain. SPRMs have the potential to become a novel treatment of uterine fibroids and endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

MeSH descriptors

Endometriosis Leiomyoma Receptors, Progesterone Receptors, Progesterone Uterine Neoplasms Animals Animals Clinical Trials as Topic Clinical Trials as Topic Endometriosis Endometriosis Estrenes Estrenes Female Female Humans Humans Leiomyoma Leiomyoma Oximes

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:03:04.870308+00:00
License: CC0 · commercial use OK